Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 70 years old (inclusive), of any sex
- People who have been diagnosed with peripheral T-cell lymphoma, confirmed by a tissue sample test
- People whose lymphoma has come back or stopped responding to at least one previous treatment
- People who have at least one measurable area of disease that can be tracked during the trial
- People whose general health and ability to carry out daily activities meets a specific standard (called ECOG 0 or 1), and whose health has not declined in the past 2 weeks (confirm with trial site)
- People who are expected to live for at least 12 weeks
- People whose bone marrow, organs, and body systems are functioning at an adequate level
- People who are willing and able to follow all the requirements of the study
Who may not be able to join:
- People who have received any anti-cancer treatment in the 28 days before the first study dose, certain traditional Chinese medicine with anti-cancer effects in the past 14 days, or steroid hormone treatment in the past 7 days
- People who have had major surgery within 4 weeks before the first study dose
- People with serious heart or cardiovascular disease
- People who have had a stroke or mini-stroke (transient ischemic attack) within the 6 months before joining
- People with significantly reduced lung function
- People with an active infection at the time of joining
- People with an unexplained fever above 38.5°C during the screening period or on the first day of treatment
- People who are pregnant
- People with a known history of alcohol or drug misuse
- People who are currently taking certain medications that strongly affect how the body processes drugs (known as CYP inducers or inhibitors, or P-glycoprotein inhibitors) (confirm with trial site)
- People who have had an allergic reaction to the study drug or any of its ingredients in the past
- People who, in the trial doctor's judgement, have other medical conditions, additional treatments, or test results that could prevent them from safely completing the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Rong Tao, MD, Fudan University
Phone: 8621-64175590
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence and severity of AEs and SAEs; Objective response rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.